Volume 21: Issue 4 (Sep 2022): Hypertension

Whelton PK, Carey RM, Aronow WS, Casey Jr DE, Collins KJ, Dennison Himmelfarb C, et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71: e13–e115, 2018

Whelton PK, Carey RM, Aronow WS, Casey Jr DE, Collins KJ, Dennison Himmelfarb C, : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71: e13–e115, 2018)| false
• Search Google Scholar
• Export Citation

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al.; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council: Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension 72: e53–e90, 2018 PubMed

• Crossref
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, ; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council: Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension 72: e53–e90, 2018 PubMed10.1161/HYP.0000000000000084)| false
• Search Google Scholar
• Export Citation

Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, et al.: The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 167: 630–641, 2017 PubMed

• Crossref
Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, : The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 167: 630–641, 2017 PubMed10.7326/M17-0882)| false
• Search Google Scholar
• Export Citation

Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al.: The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 173: 10–20, 2020 PubMed

• Crossref
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, : The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 173: 10–20, 2020 PubMed10.7326/M20-0065)| false
• Search Google Scholar
• Export Citation

Joseph JJ, Pohlman NK, Zhao S, Kline D, Brock G, Echouffo-Tcheugui JB, et al.: Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson heart study. Circulation 143: 2355–2366, 2021 PubMed

• Crossref
Joseph JJ, Pohlman NK, Zhao S, Kline D, Brock G, Echouffo-Tcheugui JB, : Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson heart study. Circulation 143: 2355–2366, 2021 PubMed10.1161/CIRCULATIONAHA.120.050896)| false
• Search Google Scholar
• Export Citation

Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P: Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 73: 424–431, 2019 PubMed

• Crossref
Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P: Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 73: 424–431, 2019 PubMed10.1161/HYPERTENSIONAHA.118.12191)| false
• Search Google Scholar
• Export Citation

Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al.: Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 8: 1583–1590, 2013 PubMed

• Crossref
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, : Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 8: 1583–1590, 2013 PubMed10.2215/CJN.00550113)| false
• Search Google Scholar
• Export Citation

Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al.: Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int 88: 622–632, 2015 PubMed

• Crossref
Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, : Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int 88: 622–632, 2015 PubMed10.1038/ki.2015.142)| false
• Search Google Scholar
• Export Citation

Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, et al.; CRIC Study Investigators: Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the chronic renal insufficiency cohort study. Hypertension 67: 387–396, 2016 PubMed

• Crossref
Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, ; CRIC Study Investigators: Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the chronic renal insufficiency cohort study. Hypertension 67: 387–396, 2016 PubMed10.1161/HYPERTENSIONAHA.115.06487)| false
• Search Google Scholar
• Export Citation

Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D: Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 10: 493–499, 2016 PubMed

• Crossref
Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D: Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 10: 493–499, 2016 PubMed10.1016/j.jash.2016.03.186)| false
• Search Google Scholar
• Export Citation

Ruzicka M, Leenen FHH, Ramsay T, Bugeja A, Edwards C, McCormick B, et al.: Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 179: 1433–1434, 2019 PubMed

• Crossref
Ruzicka M, Leenen FHH, Ramsay T, Bugeja A, Edwards C, McCormick B, : Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 179: 1433–1434, 2019 PubMed10.1001/jamainternmed.2019.1455)| false
• Search Google Scholar
• Export Citation

Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al.: Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 62: 691–697, 2013 PubMed

• Crossref
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, : Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 62: 691–697, 2013 PubMed10.1161/HYPERTENSIONAHA.113.01448)| false
• Search Google Scholar
• Export Citation

Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046–1058, 2011 PubMed

• Crossref
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046–1058, 2011 PubMed10.1161/CIRCULATIONAHA.111.030189)| false
• Search Google Scholar
• Export Citation

McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al.: A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 24: 2096–2103, 2013 PubMed

• Crossref
McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, : A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 24: 2096–2103, 2013 PubMed10.1681/ASN.2013030285)| false
• Search Google Scholar
• Export Citation

Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J: The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis. Lancet Public Health 2: e108–e120, 2017 PubMed

• Crossref
Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J: The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis. Lancet Public Health 2: e108–e120, 2017 PubMed10.1016/S2468-2667(17)30003-8)| false
• Search Google Scholar
• Export Citation

Lopes S, Mesquita-Bastos J, Garcia C, Bertoquini S, Ribau V, Teixeira M, et al.: Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol 6: 1317–1323, 2021 PubMed

• Crossref
Lopes S, Mesquita-Bastos J, Garcia C, Bertoquini S, Ribau V, Teixeira M, : Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol 6: 1317–1323, 2021 PubMed10.1001/jamacardio.2021.2735)| false
• Search Google Scholar
• Export Citation

De la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al.: Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 30: 1211–1216, 2012 PubMed

• Crossref
De la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, : Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 30: 1211–1216, 2012 PubMed10.1097/HJH.0b013e328353634e)| false
• Search Google Scholar
• Export Citation

De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al.: Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898–902, 2011 PubMed

• Crossref
De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, : Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898–902, 2011 PubMed10.1161/HYPERTENSIONAHA.110.168948)| false
• Search Google Scholar
• Export Citation

Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR: Cardiovascular events and mortality in white coat hypertension: A systematic review and meta-analysis. Ann Intern Med 170: 853–862, 2019 PubMed

• Crossref
Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR: Cardiovascular events and mortality in white coat hypertension: A systematic review and meta-analysis. Ann Intern Med 170: 853–862, 2019 PubMed10.7326/M19-0223)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Kline GA, Leung AA: How common is primary aldosteronism? Curr Opin Nephrol Hypertens 30: 353–360, 2021 PubMed

• Crossref
Hundemer GL, Kline GA, Leung AA: How common is primary aldosteronism? Curr Opin Nephrol Hypertens 30: 353–360, 2021 PubMed10.1097/MNH.0000000000000702)| false
• Search Google Scholar
• Export Citation

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al.: The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 1889–1916, 2016 PubMed

• Crossref
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, : The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 1889–1916, 2016 PubMed10.1210/jc.2015-4061)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Baudrand R, Brown JM, Curhan G, Williams GH, Vaidya A: Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity. J Clin Endocrinol Metab 102: 1835–1843, 2017 PubMed

• Crossref
Hundemer GL, Baudrand R, Brown JM, Curhan G, Williams GH, Vaidya A: Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity. J Clin Endocrinol Metab 102: 1835–1843, 2017 PubMed10.1210/jc.2016-3867)| false
• Search Google Scholar
• Export Citation

Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33–41, 2004 PubMed

• Crossref
Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, : Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33–41, 2004 PubMed10.1056/NEJMoa033263)| false
• Search Google Scholar
• Export Citation

Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al.: Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49: 846–856, 2007 PubMed

• Crossref
Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, : Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49: 846–856, 2007 PubMed10.1161/01.HYP.0000258554.87444.91)| false
• Search Google Scholar
• Export Citation

Kim SK, McCurley AT, DuPont JJ, Aronovitz M, Moss ME, Stillman IE, et al.: Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension 71: 609–621, 2018 PubMed

• Crossref
Kim SK, McCurley AT, DuPont JJ, Aronovitz M, Moss ME, Stillman IE, : Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension 71: 609–621, 2018 PubMed10.1161/HYPERTENSIONAHA.117.10437)| false
• Search Google Scholar
• Export Citation

Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al.: Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 6: 41–50, 2018 PubMed

• Crossref
Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, : Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 6: 41–50, 2018 PubMed10.1016/S2213-8587(17)30319-4)| false
• Search Google Scholar
• Export Citation

Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al.: Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2: e93136, 2017 PubMed

• Crossref
Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, : Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2: e93136, 2017 PubMed10.1172/jci.insight.93136)| false
• Search Google Scholar
• Export Citation

Monticone S, Sconfienza E, D’Ascenzo F, Buffolo F, Satoh F, Sechi LA, et al.: Renal damage in primary aldosteronism: A systematic review and meta-analysis. J Hypertens 38: 3–12, 2020 PubMed

• Crossref
Monticone S, Sconfienza E, D’Ascenzo F, Buffolo F, Satoh F, Sechi LA, : Renal damage in primary aldosteronism: A systematic review and meta-analysis. J Hypertens 38: 3–12, 2020 PubMed10.1097/HJH.0000000000002216)| false
• Search Google Scholar
• Export Citation

Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V: Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med 174: 289–297, 2021 PubMed

• Crossref
Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V: Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med 174: 289–297, 2021 PubMed10.7326/M20-4873)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, et al.: Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension 79: 178–186, 2021 PubMed

• Crossref
Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, : Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension 79: 178–186, 2021 PubMed10.1161/HYPERTENSIONAHA.121.18118)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Vaidya A: Primary aldosteronism diagnosis and management: A clinical approach. Endocrinol Metab Clin North Am 48: 681–700, 2019 PubMed

• Crossref
Hundemer GL, Vaidya A: Primary aldosteronism diagnosis and management: A clinical approach. Endocrinol Metab Clin North Am 48: 681–700, 2019 PubMed10.1016/j.ecl.2019.08.002)| false
• Search Google Scholar
• Export Citation

Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, et al.: Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: A systematic review and meta-analysis. J Clin Endocrinol Metab 106: 2423–2435, 2021

• Crossref
Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, : Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: A systematic review and meta-analysis. J Clin Endocrinol Metab 106: 2423–2435, 202110.1210/clinem/dgab348)| false
• Search Google Scholar
• Export Citation

Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al.: Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 151: 329–337, 2009 PubMed

• Crossref
Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, : Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 151: 329–337, 2009 PubMed10.7326/0003-4819-151-5-200909010-00007)| false
• Search Google Scholar
• Export Citation

Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators: Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5: 689–699, 2017 PubMed

• Crossref
Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, ; Primary Aldosteronism Surgery Outcome (PASO) investigators: Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5: 689–699, 2017 PubMed10.1016/S2213-8587(17)30135-3)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72: 658–666, 2018 PubMed

• Crossref
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72: 658–666, 2018 PubMed10.1161/HYPERTENSIONAHA.118.11568)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 6: 51–59, 2018 PubMed

• Crossref
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 6: 51–59, 2018 PubMed10.1016/S2213-8587(17)30367-4)| false
• Search Google Scholar
• Export Citation

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 3: 768–774, 2018 PubMed

• Crossref
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 3: 768–774, 2018 PubMed10.1001/jamacardio.2018.2003)| false
• Search Google Scholar
• Export Citation

Köhler A, Sarkis AL, Heinrich DA, Müller L, Handgriff L, Deniz S, et al.: Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: A cohort study. Eur J Endocrinol 185: 663–672, 2021 PubMed

• Crossref
Köhler A, Sarkis AL, Heinrich DA, Müller L, Handgriff L, Deniz S, : Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: A cohort study. Eur J Endocrinol 185: 663–672, 2021 PubMed10.1530/EJE-21-0018)| false
• Search Google Scholar
• Export Citation

Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A: Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 101: 3989–3996, 2016 PubMed

• Crossref
Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A: Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 101: 3989–3996, 2016 PubMed10.1210/jc.2016-1963)| false
• Search Google Scholar
• Export Citation

Lerman LO, Textor SC, Grande JP: Mechanisms of tissue injury in renal artery stenosis: Ischemia and beyond. Prog Cardiovasc Dis 52: 196–203, 2009 PubMed

• Crossref
Lerman LO, Textor SC, Grande JP: Mechanisms of tissue injury in renal artery stenosis: Ischemia and beyond. Prog Cardiovasc Dis 52: 196–203, 2009 PubMed10.1016/j.pcad.2009.09.002)| false
• Search Google Scholar
• Export Citation

De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, et al.: Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol 48: 1851–1855, 2006 PubMed

• Crossref
De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, : Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol 48: 1851–1855, 2006 PubMed10.1016/j.jacc.2006.05.074)| false
• Search Google Scholar
• Export Citation

Drieghe B, Madaric J, Sarno G, Manoharan G, Bartunek J, Heyndrickx GR, et al.: Assessment of renal artery stenosis: Side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. Eur Heart J 29: 517–524, 2008 PubMed

• Crossref
Drieghe B, Madaric J, Sarno G, Manoharan G, Bartunek J, Heyndrickx GR, : Assessment of renal artery stenosis: Side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. Eur Heart J 29: 517–524, 2008 PubMed10.1093/eurheartj/ehm631)| false
• Search Google Scholar
• Export Citation

Herrmann SM, Textor SC: Renovascular hypertension. Endocrinol Metab Clin North Am 48: 765–778, 2019 PubMed

• Crossref
Herrmann SM, Textor SC: Renovascular hypertension. Endocrinol Metab Clin North Am 48: 765–778, 2019 PubMed10.1016/j.ecl.2019.08.007)| false
• Search Google Scholar
• Export Citation

Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al.: The United States Registry for Fibromuscular Dysplasia: Results in the first 447 patients. Circulation 125: 3182–3190, 2012 PubMed

• Crossref
Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, : The United States Registry for Fibromuscular Dysplasia: Results in the first 447 patients. Circulation 125: 3182–3190, 2012 PubMed10.1161/CIRCULATIONAHA.112.091223)| false
• Search Google Scholar
• Export Citation

Herrmann SM, Textor SC: Current concepts in the treatment of renovascular hypertension. Am J Hypertens 31: 139–149, 2018 PubMed

• Crossref
Herrmann SM, Textor SC: Current concepts in the treatment of renovascular hypertension. Am J Hypertens 31: 139–149, 2018 PubMed10.1093/ajh/hpx154)| false
• Search Google Scholar
• Export Citation

Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al.; CORAL Investigators: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370: 13–22, 2014 PubMed

• Crossref
Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, ; CORAL Investigators: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370: 13–22, 2014 PubMed10.1056/NEJMoa1310753)| false
• Search Google Scholar
• Export Citation

Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al.; ASTRAL Investigators: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361: 1953–1962, 2009 PubMed

• Crossref
Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, ; ASTRAL Investigators: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361: 1953–1962, 2009 PubMed10.1056/NEJMoa0905368)| false
• Search Google Scholar
• Export Citation

Bax L, Woittiez AJ, Kouwenberg HJ, Mali WPTM. Buskens E. Beek FJA et al.: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial. Ann Intern Med 150: 840–848, 2009 PubMed

• Crossref
Bax L, Woittiez AJ, Kouwenberg HJ, Mali WPTM. Buskens E. Beek FJA: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial. Ann Intern Med 150: 840–848, 2009 PubMed10.7326/0003-4819-150-12-200906160-00119)| false
• Search Google Scholar
• Export Citation

Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, et al.: Angiotensin inhibition in renovascular disease: A population-based cohort study. Am Heart J 156: 549–555, 2008 PubMed

• Crossref
Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, : Angiotensin inhibition in renovascular disease: A population-based cohort study. Am Heart J 156: 549–555, 2008 PubMed10.1016/j.ahj.2008.05.013)| false
• Search Google Scholar
• Export Citation

Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR: SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv 84: 1163–1171, 2014 PubMed

• Crossref
Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR: SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv 84: 1163–1171, 2014 PubMed10.1002/ccd.25559)| false
• Search Google Scholar
• Export Citation

Stone PA, Campbell JE, Aburahma AF, Hamdan M, Broce M, Nanjundappa A, et al.: Ten-year experience with renal artery in-stent stenosis. J Vasc Surg 53: 1026–1031, 2011 PubMed

• Crossref
Stone PA, Campbell JE, Aburahma AF, Hamdan M, Broce M, Nanjundappa A, : Ten-year experience with renal artery in-stent stenosis. J Vasc Surg 53: 1026–1031, 2011 PubMed10.1016/j.jvs.2010.10.092)| false
• Search Google Scholar
• Export Citation

Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF: Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: A systematic review and meta-analysis. Hypertension 56: 525–532, 2010 PubMed

• Crossref
Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF: Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: A systematic review and meta-analysis. Hypertension 56: 525–532, 2010 PubMed10.1161/HYPERTENSIONAHA.110.152918)| false
• Search Google Scholar
• Export Citation

Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al.; Endocrine Society: Pheochromocytoma and paraganglioma: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99: 1915–1942, 2014 PubMed

• Crossref
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, ; Endocrine Society: Pheochromocytoma and paraganglioma: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99: 1915–1942, 2014 PubMed10.1210/jc.2014-1498)| false
• Search Google Scholar
• Export Citation

Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, et al.: Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab 104: 1386–1393, 2019 PubMed

• Crossref
Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, : Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab 104: 1386–1393, 2019 PubMed10.1210/jc.2018-01707)| false
• Search Google Scholar
• Export Citation

Stolk RF, Bakx C, Mulder J, Timmers HJ, Lenders JW: Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab 98: 1100–1106, 2013 PubMed

• Crossref
Stolk RF, Bakx C, Mulder J, Timmers HJ, Lenders JW: Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab 98: 1100–1106, 2013 PubMed10.1210/jc.2012-3669)| false
• Search Google Scholar
• Export Citation

Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Hypertension awareness, treatment, and control in adults with CKD: Results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 55: 441–451, 2010 PubMed

• Crossref
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, ; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Hypertension awareness, treatment, and control in adults with CKD: Results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 55: 441–451, 2010 PubMed10.1053/j.ajkd.2009.09.014)| false
• Search Google Scholar
• Export Citation

De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al.: Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61: 2461–2467, 2013 PubMed

• Crossref
De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, : Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61: 2461–2467, 2013 PubMed10.1016/j.jacc.2012.12.061)| false
• Search Google Scholar
• Export Citation

Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745–753, 2002 PubMed

• Crossref
Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745–753, 2002 PubMed10.1681/ASN.V133745)| false
• Search Google Scholar
• Export Citation

Lee S, Oh HJ, Lee EK, Lee O, Ha E, Kim SJ, et al.: Blood pressure control during chronic kidney disease progression. Am J Hypertens 30: 610–616, 2017 PubMed

• Crossref
Lee S, Oh HJ, Lee EK, Lee O, Ha E, Kim SJ, : Blood pressure control during chronic kidney disease progression. Am J Hypertens 30: 610–616, 2017 PubMed10.1093/ajh/hpx017)| false
• Search Google Scholar
• Export Citation

Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, et al.: Obstructive sleep apnea and resistant hypertension: A case-control study. Chest 132: 1858–1862, 2007 PubMed

• Crossref
Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, : Obstructive sleep apnea and resistant hypertension: A case-control study. Chest 132: 1858–1862, 2007 PubMed10.1378/chest.07-1170)| false
• Search Google Scholar
• Export Citation

Chee MR, Hoo J, Libianto R, Gwini SM, Hamilton G, Narayan O, et al.: Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea. Hypertension 77: 2094–2103, 2021 PubMed

• Crossref
Chee MR, Hoo J, Libianto R, Gwini SM, Hamilton G, Narayan O, : Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea. Hypertension 77: 2094–2103, 2021 PubMed10.1161/HYPERTENSIONAHA.120.16902)| false
• Search Google Scholar
• Export Citation

Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131: 453–459, 2007 PubMed

• Crossref
Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131: 453–459, 2007 PubMed10.1378/chest.06-1442)| false
• Search Google Scholar
• Export Citation

Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, et al.: Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens 38: 464–468, 2016 PubMed

• Crossref
Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, : Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens 38: 464–468, 2016 PubMed10.3109/10641963.2015.1131290)| false
• Search Google Scholar
• Export Citation

Bratton DJ, Gaisl T, Wons AM, Kohler M: CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: A systematic review and meta-analysis. JAMA 314: 2280–2293, 2015 PubMed

• Crossref
Bratton DJ, Gaisl T, Wons AM, Kohler M: CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: A systematic review and meta-analysis. JAMA 314: 2280–2293, 2015 PubMed10.1001/jama.2015.16303)| false
• Search Google Scholar
• Export Citation

McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al.; SAVE Investigators and Coordinators: CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375: 919–931, 2016 PubMed

• Crossref
McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, ; SAVE Investigators and Coordinators: CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375: 919–931, 2016 PubMed10.1056/NEJMoa1606599)| false
• Search Google Scholar
• Export Citation

Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al.: 2018 AHA/ACC guideline for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 73: e81–e192, 2019 PubMed

• Crossref
Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, : 2018 AHA/ACC guideline for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 73: e81–e192, 2019 PubMed10.1016/j.jacc.2018.08.1029)| false
• Search Google Scholar
• Export Citation

Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289–300, 1994 PubMed

• Crossref
Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289–300, 1994 PubMed10.7326/0003-4819-121-4-199408150-00011)| false
• Search Google Scholar
• Export Citation

Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94: 483–489, 1996 PubMed

• Crossref
Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, : Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94: 483–489, 1996 PubMed10.1161/01.CIR.94.3.483)| false
• Search Google Scholar
• Export Citation

Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 53: 120–127, 2017 PubMed

• Crossref
Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 53: 120–127, 2017 PubMed10.1016/j.ctrv.2016.12.002)| false
• Search Google Scholar
• Export Citation

Mir O, Ropert S, Alexandre J, Goldwasser F: Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20: 967–970, 2009 PubMed

• Crossref
Mir O, Ropert S, Alexandre J, Goldwasser F: Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20: 967–970, 2009 PubMed10.1093/annonc/mdp206)| false
• Search Google Scholar
• Export Citation

Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, et al.; ERCUSYN Study Group: The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165: 383–392, 2011 PubMed

• Crossref
Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, ; ERCUSYN Study Group: The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165: 383–392, 2011 PubMed10.1530/EJE-11-0272)| false
• Search Google Scholar
• Export Citation

Nieman LK: Hypertension and cardiovascular mortality in patients with Cushing syndrome. Endocrinol Metab Clin North Am 48: 717–725, 2019 PubMed

• Crossref
Nieman LK: Hypertension and cardiovascular mortality in patients with Cushing syndrome. Endocrinol Metab Clin North Am 48: 717–725, 2019 PubMed10.1016/j.ecl.2019.08.005)| false
• Search Google Scholar
• Export Citation

Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al.: Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385: 2507–2519, 2021 PubMed

• Crossref
Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, : Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385: 2507–2519, 2021 PubMed10.1056/NEJMoa2110730)| false
• Search Google Scholar
• Export Citation

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al.; British Hypertension Society’s PATHWAY Studies Group: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 386: 2059–2068, 2015 PubMed

• Crossref
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, ; British Hypertension Society’s PATHWAY Studies Group: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 386: 2059–2068, 2015 PubMed10.1016/S0140-6736(15)00257-3)| false
• Search Google Scholar
• Export Citation

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al.; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6: 464–475, 2018 PubMed

• Crossref
Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6: 464–475, 2018 PubMed10.1016/S2213-8587(18)30071-8)| false
• Search Google Scholar
• Export Citation